Palisade Bio, Inc. develops next-generation oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for targeted delivery and selective bioactivation in the ileum and colon, with clinical development focused on ulcerative colitis and Crohn’s disease.
Company news commonly covers PALI-2108 clinical and translational data, pharmacokinetic and biomarker findings, disease-conference presentations, clinical advisory activity and healthcare investor events. Updates also describe the company’s precision pharmacology strategy and the role of gut-targeted PDE4 inhibition in inflammatory bowel disease programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Palisade Bio, a biopharmaceutical company focused on gastrointestinal therapies, has received Canadian Patent No. 2,942,358 for LB1148, a serine protease inhibitor that may reduce intestinal damage by neutralizing digestive enzymes. This patent extends protection until 2035. The patent covers the composition of LB1148, which has shown promising results in clinical studies for reducing post-surgical abdominal adhesions and improving gastrointestinal function. Currently, LB1148 is undergoing a Phase 2 study to evaluate its effectiveness in subjects undergoing elective bowel resection, with topline data expected in Q2 2023. The CEO emphasized the importance of strengthening the intellectual property portfolio around LB1148 as part of their development strategy.
Palisade Bio (Nasdaq: PALI) announced the enrollment of the first patient in a Phase 3 clinical trial for LB1148, conducted by its partner Newsoara Biopharma in China. This milestone is expected to advance the development of LB1148, a serine protease inhibitor aimed at protecting gastrointestinal integrity in surgery patients. The double-blind, randomized trial will evaluate LB1148's efficacy in accelerating bowel function post-abdominal surgery. Achieving clinical and regulatory milestones will trigger payments to Palisade, enhancing its financial outlook as it potentially brings LB1148 to a wider patient base.